Clinical Trials Browser

Phase 2/3 × UNKNOWN × Breast Neoplasms × Clear all

NCT01150513 2021-02-09

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Phase 2/3 Completed

Breast Neoplasms